Pharmacotherapy of Essential Tremor
Open Access
- 1 January 2013
- journal article
- review article
- Published by SAGE Publications in Journal of Central Nervous System Disease
- Vol. 5, 43-55
- https://doi.org/10.4137/jcnsd.s6561
Abstract
Essential tremor (ET) is a common movement disorder but its pathogenesis remains poorly understood. This has limited the development of effective pharmacotherapy. The current therapeutic armamentaria for ET represent the product of careful clinical observation rather than targeted molecular modeling. Here we review their pharmacokinetics, metabolism, dosing, and adverse effect profiles and propose a treatment algorithm. We also discuss the concept of medically refractory tremor, as therapeutic trials should be limited unless invasive therapy is contraindicated or not desired by patients.Keywords
This publication has 147 references indexed in Scilit:
- Exome Sequencing Identifies FUS Mutations as a Cause of Essential TremorAmerican Journal of Human Genetics, 2012
- Quantitative gait analysis in essential tremor reveals impairments that are maintained into advanced ageGait & Posture, 2011
- How are we doing with the treatment of essential tremor (ET)?European Journal of Neurology, 2010
- Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological studyMovement Disorders, 2010
- Essential TremorsArchives of Neurology, 2009
- Intention tremor in essential tremor: Prevalence and association with disease durationMovement Disorders, 2009
- Reappraisal of the role of the DRD3 gene in essential tremorParkinsonism & Related Disorders, 2008
- Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremorNeuroToxicology, 2008
- A functional variant of the dopamine D 3 receptor is associated with risk and age-at-onset of essential tremorProceedings of the National Academy of Sciences of the United States of America, 2006
- Drug-Induced Movement DisordersDrug Safety, 1997